CD52 and myeloproliferative disorder: The JAK2 inhibitors did not substantially up‐ or down‐regulate the expression of other target antigens, such as CD26, CD44, CD47, CD52, CD97, CD135, CD184, CD206, CD243, or EPOR on MPN NSC (Figure 4).